Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study

Evidence on everolimus in breast cancer has placed hyperglycemia among the most common high grade adverse events. Anthropometrics and biomarkers of glucose metabolism were investigated in a observational study of 102 postmenopausal, HR + HER2- metastatic breast cancer patients treated with everolimu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Pizzuti, Laura, Marchetti, Paolo, Natoli, Clara, Gamucci, Teresa, Santini, Daniele, Scinto, Angelo Fedele, Iezzi, Laura, Mentuccia, Lucia, D’Onofrio, Loretta, Botticelli, Andrea, Moscetti, Luca, Sperati, Francesca, Botti, Claudio, Ferranti, Francesca, Buglioni, Simonetta, Sanguineti, Giuseppe, Di Filippo, Simona, di Lauro, Luigi, Sergi, Domenico, Catenaro, Teresa, Tomao, Silverio, Giordano, Antonio, Maugeri-Saccà, Marcello, Barba, Maddalena, Vici, Patrizia
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5587713/
https://ncbi.nlm.nih.gov/pubmed/28878375
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-10061-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados